Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
EMA says Lilly's weight-loss drug does not need separate approval for sleep apnea
The European Medicines Agency stated Eli Lilly’s weight-loss drug, Mounjaro, does not require separate approval for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, as its use for weight management already covers this.
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug
EMA’s CHMP adopted a positive opinion for Novo Nordisk’s Ozempic label update based on FLOW trial data, showing 24% risk reduction in kidney disease progression, cardiovascular disease, and kidney death. Semaglutide 1.0 mg also reduced major cardiovascular events by 18% and all-cause mortality by 20%. Novo Nordisk filed for US label expansion, with a decision expected in H1 2025.
Eli Lilly to test weight loss drug Zepbound for drug and alcohol addiction
Eli Lilly plans to test Zepbound, a GLP-1 weight-loss drug, as a treatment for alcohol and drug addiction starting next year. Evidence suggests GLP-1 medications could help with substance use disorders by reducing the desire cycle. Eli Lilly will be the first to conduct clinical trials specifically focused on addiction treatment.
GLP-1 drug compounding is in limbo. Will the FDA draw out its decision?
The FDA's removal of Eli Lilly's Zepbound and Mounjaro from the drug shortage list in October led to a legal battle between the FDA and compound manufacturers, with the FDA temporarily allowing compound pharmacies to resume activities. The FDA is considering adding GLP-1 drugs to a new list that would prohibit compounding, but has not finalized the rule. The incoming Trump administration may influence future decisions on GLP-1 medications, including potential coverage by Medicare and Medicaid.
GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?
The FDA's decision on Eli Lilly's Zepbound and Mounjaro left compounders in limbo, affecting GLP-1 drug access. The FDA reversed course, allowing compounding to resume, but the future remains uncertain. Eli Lilly and Novo Nordisk, major GLP-1 drugmakers, have faced shortages and lawsuits against compounders. The FDA proposed a list to restrict compounding, but has yet to finalize it. With a new presidential administration incoming, the FDA may delay final decisions on GLP-1 drugs.
Will Eli Lilly's blockbuster obesity drug be available in India by 2025?
Eli Lilly plans to launch tirzepatide (Mounjaro, Zepbound) in India by 2025, pending regulatory approvals. The SEC reviewed a multi-dose pen version but requested interim efficacy data from India-specific Phase IV trials. Tirzepatide, approved for diabetes and obesity, activates GIP and GLP-1 pathways to regulate blood sugar. Eli Lilly remains committed to launching the drug in India despite regulatory delays.
GLP-1 Meds, such as Ozempic or Mounjaro, May Lower Clot Risk in People With Diabetes
GLP-1 meds like Ozempic or Mounjaro may reduce venous thromboembolism (VTE) risk by 20% in people with diabetes, compared to other diabetes drugs, according to a study presented at the American Society of Hematology meeting.
GLP-1 Meds May Lower Clot Risk in People With Diabetes
GLP-1 meds like Ozempic or Mounjaro may reduce venous thromboembolism (VTE) risk by 20% in people with diabetes compared to other diabetes drugs, according to a study presented at the American Society of Hematology meeting.
Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue
Novo Holdings' $16.5 billion acquisition of Catalent aims to resolve Novo Nordisk's supply issues for weight-loss drugs, with plans to resell fill-finish sites to Novo Nordisk from 2026. Both companies expect the transaction to close by end of 2024. Despite investments in manufacturing capacity, Novo and Eli Lilly face potential market overestimation of demand for their weight-loss drugs, as evidenced by recent stock declines.
Popular US-based weight loss drug maker Eli Lilly plans to launch medicine in India next year
Eli Lilly plans to introduce Tirzepatide, marketed as Mounjaro, to India in 2025, targeting type 2 diabetes and obesity. The move aligns with the company's strategy to expand its portfolio in India, considering local affordability and value. Eli Lilly has been operating in India since 1993, collaborating with local firms for its diabetes portfolio, and aims to address India's growing healthcare challenges.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath